In a quiet corner of medical inquiry, researchers at the University of Cambridge have looked backward through the records of nearly thirty thousand older patients and noticed something worth pausing over: those who had been given lithium, a drug long used to steady the swings of mood, seemed less likely to slip into dementia. The world is already carrying a heavy and growing weight of this illness, and any hint of a gentler path draws careful attention. Yet the finding is an echo, not yet a answer, since the lithium-treated group was small and the evidence was gathered from what had already ha
Lithium Linked to Lower Dementia Risk in Cambridge-Led Study, Though Evidence Remains Preliminary
It's far too early to say for sure
In a quiet corner of medical inquiry, researchers at the University of Cambridge have looked backward through the records of nearly thirty thousand older patients and noticed something worth pausing over: those who had been given lithium, a drug long used to steady the swings of mood, seemed less likely to slip into dementia. The world is already carrying a heavy and growing weight of this illness, and any hint of a gentler path draws careful attention. Yet the finding is an echo, not yet a answer, since the lithium-treated group was small and the evidence was gathered from what had already happened rather than from deliberate experiment. It is a question placed on the table, one that will need the slower work of trials before anyone can say whether the drug truly guards the mind.
Researchers at the University of Cambridge have reported a possible connection between lithium, a drug long prescribed to steady mood, and a lower chance of developing dementia. The finding comes from a review of health records for nearly 30,000 patients over the age of 50, published in PLoS Medicine.
The backdrop is sobering. More than 55 million people live with dementia worldwide, with nearly 10 million new cases each year, and it stands as the seventh leading cause of death and a major source of disability among older people.
The patients who had received lithium were less likely to develop dementia than those who had not. But the authors are candid about the limits: the lithium group was small, and because the study looked at past records rather than assigning treatment and following people forward, it can show an association without proving that lithium prevents the disease.
Lithium is usually prescribed for bipolar disorder and depression, both of which are themselves linked to higher dementia risk, so the team had to account for those conditions. Dr Shanquan Chen, the first author, said they had expected bipolar patients to be more vulnerable, yet the analysis suggested the reverse. He cautioned that it is far too early to be certain, but said lithium may reduce risk in people with bipolar disorder.
Earlier studies had explored lithium for people already diagnosed with dementia, but they were small and left open whether it could delay or prevent the illness. This work addresses that question only tentatively.
Chen framed the urgency in terms of time and cost, noting that rising case numbers strain healthcare systems and that delaying onset by five years could reduce prevalence and economic impact by as much as 40 per cent. The authors believe the results justify large randomised trials. Those trials, not this record review, will decide whether lithium truly helps.
Researchers at the University of Cambridge have reported a possible link between lithium, a drug long used to steady mood, and a lower chance of developing dementia. The finding comes from a look back at the health records of nearly 30,000 patients, all over the age of 50, and it was published in the journal PLoS Medicine.
The scale of the problem frames the work. More than 55 million people live with dementia worldwide, and nearly 10 million new cases are reported every year. Dementia is currently the seventh leading cause of death among all diseases, and one of the major causes of disability and dependency among older people globally.
What the team found was that patients who had received lithium were less likely to develop dementia than those who had not. The authors add a caution of their own: the number of patients in the study who were given lithium was small. The analysis was retrospective, meaning it examined records of what had already happened rather than assigning people to treatment and following them forward. That design can show an association, but it cannot establish that lithium prevents dementia.
Lithium is a mood stabiliser, usually prescribed for bipolar affective disorder and depression. That created a complication the researchers had to handle. Bipolar disorder and depression are themselves considered to raise the risk of dementia, so the analysis had to account for them. First author Dr Shanquan Chen, of Cambridge's Department of Psychiatry, said as much.
The team had expected something specific. Because bipolar disorder is the most common reason lithium is prescribed, they anticipated that patients with the condition would be more likely to develop dementia. According to Chen, their analysis suggested the opposite. He stressed it was far too early to say for sure, but said it is possible lithium might reduce dementia risk in people with bipolar disorder.
Earlier research had pointed to lithium as a possible treatment for people already diagnosed with dementia or showing early cognitive impairment. Those studies were limited in size, and it has remained unclear whether the drug could delay or prevent dementia from developing at all. The new work speaks to that second question, though only tentatively.
Chen put the stakes in terms of time and cost. The number of people with dementia keeps growing, he said, putting huge pressure on healthcare systems, and it has been estimated that delaying onset by just five years could cut prevalence and economic impact by as much as 40 per cent.
The authors say the results support the idea that lithium could become a preventative treatment and could be taken forward into large randomised controlled trials. Chen added that further experimental medicine and clinical studies are needed to determine whether lithium truly helps. Those trials, not this record review, would be the test to watch.
Notable Quotes
It's far too early to say for sure, but it's possible that lithium might reduce the risk of dementia in people with bipolar disorder.— Dr Shanquan Chen, University of Cambridge
Delaying the onset of dementia by just five years could reduce its prevalence and economic impact by as much as 40 per cent.— Dr Shanquan Chen, paraphrasing an estimate
Want the full story?
Read the original at News18 ↗
Education